683 Capital Management LLC Has $1.03 Million Position in Pyxis Oncology, Inc. $PYXS

683 Capital Management LLC increased its position in Pyxis Oncology, Inc. (NASDAQ:PYXS) by 69.9% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 891,910 shares of the company’s stock after acquiring an additional 366,910 shares during the period. 683 Capital Management LLC’s holdings in Pyxis Oncology were worth $1,026,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Laurion Capital Management LP increased its holdings in Pyxis Oncology by 32.3% in the fourth quarter. Laurion Capital Management LP now owns 4,796,479 shares of the company’s stock worth $5,516,000 after buying an additional 1,170,505 shares during the last quarter. Vanguard Group Inc. increased its holdings in Pyxis Oncology by 0.7% in the third quarter. Vanguard Group Inc. now owns 2,163,962 shares of the company’s stock worth $4,804,000 after buying an additional 14,566 shares during the last quarter. Jane Street Group LLC increased its holdings in Pyxis Oncology by 158.8% in the fourth quarter. Jane Street Group LLC now owns 786,010 shares of the company’s stock worth $904,000 after buying an additional 482,310 shares during the last quarter. Renaissance Technologies LLC increased its holdings in Pyxis Oncology by 26.4% in the fourth quarter. Renaissance Technologies LLC now owns 728,380 shares of the company’s stock worth $838,000 after buying an additional 152,044 shares during the last quarter. Finally, Atle Fund Management AB acquired a new position in Pyxis Oncology in the fourth quarter worth approximately $710,000. Institutional investors and hedge funds own 39.07% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the company. Wall Street Zen downgraded Pyxis Oncology from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Wedbush initiated coverage on shares of Pyxis Oncology in a research report on Tuesday, May 5th. They issued an “outperform” rating and a $6.00 price target on the stock. Stifel Nicolaus dropped their price target on shares of Pyxis Oncology from $9.00 to $8.00 and set a “buy” rating on the stock in a research report on Tuesday, March 24th. Weiss Ratings raised shares of Pyxis Oncology from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, June 5th. Finally, HC Wainwright reissued a “buy” rating and issued a $7.00 price target on shares of Pyxis Oncology in a research report on Tuesday, March 24th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Pyxis Oncology currently has a consensus rating of “Moderate Buy” and an average target price of $6.83.

Pyxis Oncology Trading Up 8.6%

Shares of Pyxis Oncology stock opened at $1.90 on Thursday. The company’s fifty day simple moving average is $1.87 and its 200-day simple moving average is $1.88. The company has a market cap of $120.37 million, a price-to-earnings ratio of -1.45 and a beta of 1.42. Pyxis Oncology, Inc. has a 1 year low of $0.97 and a 1 year high of $5.55.

Pyxis Oncology (NASDAQ:PYXS) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.02). As a group, research analysts forecast that Pyxis Oncology, Inc. will post -1.23 earnings per share for the current fiscal year.

About Pyxis Oncology

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.